Biomarker Core

项目总结 Biomarker Core(BC)的使命是支持阿尔茨海默病(AD)和AD相关痴呆 (AD/ADRD)通过收集、存储、跟踪、共享和分析生物标本和 相关的临床、遗传和生物标记物数据。收集的临床、遗传和生物标记物数据 人类生物菌种的多样性将有助于理解AD/ADRD潜在的异质性 对目前储存在 克利夫兰阿尔茨海默病研究中心(CADRC)。这些信息将有助于改进 在独特的、研究不足的人群以及整个人群中进行诊断。为了实现这一使命，我们 以前在CASE之间建立和整合了生物样品收集和研究合作 西部储备大学、克利夫兰诊所、MetroHealth系统、大学医院和路易斯斯托克 克利夫兰退伍军人医疗中心。BC的目标是1)通过利用和扩展 CADRC BC基础设施和生物标本与综合数据库中的参与者临床数据相关联 并继续包括纵向生物样品收集，2)提供基本生物标记物表征以 促进AD/ADRD研究，3)提供基本的基因特征，以促进AD/ADRD研究，以及4) 向神经退行性疾病联盟和协调中心分发生物样品，以及 内部和外部调查人员。为了实现这些目标，我们的专家团队将继续作出贡献 为CADRC收集的生物制品。CADRC BC的建立提供了一个必要的 基础设施，以促进和整合独特和未得到充分研究的人群的独立项目，如 作为非裔美国人，以及未被充分研究的神经退行性疾病，包括非典型AD和 路易体痴呆。标准临床数据(统一数据集)来自这些不同的未被研究的 种群将继续与生成的生物标记物和遗传数据相联系。遗传和生物标记物数据 根据国家阿尔茨海默氏症项目法(NPA)的目标，与相关临床数据相关联的是 与科学界共享，包括阿尔茨海默病遗传联合会(ADGC)，国家 阿尔茨海默氏症协调中心(NACC)和国家阿尔茨海默氏病老龄遗传学研究所 数据存储(NIAGADS)。已经建立的CCLRCBH-生物库和我们训练有素的人员 保险无缝创建的CADRC BC。重要的是，CADRC BC基础设施现已到位 促进未来创新的AD/ADRD研究项目，以增强我们对异质性的理解 AD/ADRD的病理学特征。

PROJECT SUMMARY The mission of the Biomarker Core (BC) is to support Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) research projects by collecting, storing, tracking, sharing, and analyzing biospecimens and associated clinical, genetic, and biomarker data. The collected clinical, genetic, and biomarker data on a variety of human biospecimens will contribute to the understanding of AD/ADRD underlying heterogeneity by cataloging the onset, progression, and disease symptoms of participant biospecimens currently stored in the Cleveland Alzheimer's Disease Research Center (CADRC) BC. This information will contribute to improving diagnosis in unique, understudied populations, as well as the population as a whole. Toward this mission, we previously established and integrated biospecimen collection and research collaborations between Case Western Reserve University, Cleveland Clinic, MetroHealth Systems, University Hospitals, and the Louis Stoke Cleveland VA Medical Center. The aims of the BC are to 1) Facilitate research by leveraging and expanding the CADRC BC infrastructure and biospecimens linked with participant clinical data in the integrated database and continue to include longitudinal biospecimen collection, 2) Provide basic biomarker characterization to facilitate AD/ADRD research, 3) Provide basic genetic characterization to facilitate AD/ADRD research, and 4) Distribute biospecimens to neurodegenerative disease consortiums and coordinating centers, as well as to internal and external investigators. Toward these aims, our team of experts will continue to contribute to biospecimen collection for the CADRC. The establishment of the CADRC BC has provided an essential infrastructure to facilitate and integrate the independent projects of unique and understudied populations, such as African Americans, as well as understudied neurodegenerative disorders, including atypical AD and dementia with Lewy bodies. Standard clinical data (the Uniform Data Set) from these diverse understudied populations will continue to be linked with generated biomarker and genetic data. Genetic and biomarker data linked to relevant clinical data in accordance with goals of the National Alzheimer's Project Act (NAPA) are shared with the scientific community including the Alzheimer's Disease Genetic Consortium (ADGC), National Alzheimer's Coordinating Center (NACC), and the National Institute on Aging Genetics of Alzheimer's Disease Data Storage (NIAGADS). The already established CCLRCBH-Biobank and our highly trained personnel has insured seamless creation of the CADRC BC. Importantly, the CADRC BC infrastructure is now in place to facilitate future innovative AD/ADRD research projects that enhances our understanding of the heterogeneity of AD/ADRD pathology.